GlassScriptPhysician profile
Charles Morris
NPI 1861029191
$1,838.57
in general payments reported to CMS, 2019-2025
17 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $252 · 2024: $793 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $319.39 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $289.04 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.38 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $194.27 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Glaxosmithkline, LLC. | $190.93 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.70 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $91.09 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $75.64 | 2024-2025 | |
| Astellas Pharma US INC | $71.69 | 2024-2025 | Veozah |
| Dynavax Technologies Corporation | $67.97 | 2024-2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.91 | 2024 | Ofev |
| Phathom Pharmaceuticals, INC. | $28.56 | 2025 | Voquezna |
| Amgen INC. | $21.75 | 2025 | Krystexxa |
| Cook Medical LLC | $20.63 | 2024 | Zenith |
| Eisai INC. | $19.44 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.29 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.89 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.